Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05507346
Other study ID # KCT 009 (TEAYS)
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 6, 2022
Est. completion date January 9, 2024

Study information

Verified date March 2024
Source Koya Medical, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the Koya wearable device - a Novel Portable Non-Pneumatic Active Compression Device (NPCD) in contrast to an advanced pneumatic compression device (APCD)


Description:

A Multi-center Randomized Control Single Cross-over Study to Evaluate the Safety and Effectiveness of Dayspring, a Novel Portable Non-Pneumatic Active Compression Device (NPCD) vs. an Advanced Pneumatic Compression Device (APCD) for Treating Lower Extremity Lymphedema. To evaluate the Dayspring, a Novel Portable Non-Pneumatic Active Compression Device (NPCD) in contrast to an advanced pneumatic compression device (APCD) in a multi-centered setting to evaluate volume, quality of life, safety, adherence, and preference.


Recruitment information / eligibility

Status Completed
Enrollment 121
Est. completion date January 9, 2024
Est. primary completion date January 9, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: - Males and females = 18 years of age - Capable and willing to sign the informed consent and deemed capable of following the study protocol - Subjects must have a diagnosis of primary or secondary unilateral or bilateral lower extremity edema or lower extremity phlebolymphedema from chronic venous insufficiency Exclusion Criteria: - Individuals with a history or presence of a systemic disorder or condition that could place the subject at increased risk from sequential compression therapy - Inability or unwillingness to participate in all aspects of study protocol and/or inability to provide informed consent - Subjects with exam results that would prevent safe and effective use of the study device (cellulitis, open-wounds, healing-wounds, etc.) - Subjects must not have any diagnosed cognitive or physical impairment that would interfere with use of the device - Individuals who present with Ankle-brachial Index (ABI) screening score < 0.8 and > 1.30, indicating the possibility of Peripheral Arterial disease (PAD) - Diagnosis of lipedema - Diagnosis of active or recurrent cancer (< 3 months since completion of chemotherapy, radiation therapy or primary surgery for the cancer) - Diagnosis of acute infection (in the last four weeks) - Diagnosis of acute thrombophlebitis (in last 6 months) - Diagnosis of pulmonary embolism or deep vein thrombosis within the previous 6 months - Diagnosis of pulmonary edema - Diagnosis of congestive heart failure (uncontrolled/uncompensated) - Diagnosis of chronic kidney disease with acute renal failure - Diagnosis of epilepsy - Subjects with poorly controlled asthma - Any condition where increased venous and lymphatic return is undesirable - Women who are pregnant, planning a pregnancy or nursing at study entry - Participation in any clinical trial of an investigational substance or device during the past 30 days

Study Design


Intervention

Device:
Cross over Device (PCD or Dayspring - alternate to first group)
Cross over after three month of use and a month of washout period

Locations

Country Name City State
United States Stanley G Rockson Oakland California

Sponsors (1)

Lead Sponsor Collaborator
Koya Medical, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Limb volume reduction or maintenance Limb volume measurement is performed by using a calibrated tape measure to measure circumference from the ankle at 4cm increments to the waist region. Measurements to be taken for both lowerr extremities. Volume is calculated based on cylindrical segment analysis. The outcome measure is assessed as a difference or change from baseline to month 3 3 months
Primary LYMQOL The Lymphedema Quality of Life Questionnaire (LYMQOL), a validated disease-specific QoL tool, is also administered at baseline and month 3. Overall QoL is scored on a single item by the patient on a scale of 1-10. The outcome measure is assessed as a difference or change from baseline LYMQOL at day zero and month 3 3 months
Primary Therapy adherence tracking A table will be provided to patient to document days of use with the device to track adherence 3 months
Secondary Safety/AEs As assessed by reported adverse events 3 months
Secondary Patient survey on preference A study survey administered at the end of the study to measure patient preference between the two devices 3 months
See also
  Status Clinical Trial Phase
Completed NCT06067880 - Surgical Intervention and Lymphatic Diseases.
Active, not recruiting NCT04797390 - A Study Evaluating an Advanced Pneumatic Compression Device Versus Usual Care for Treatment of Head and Neck Lymphedema N/A
Completed NCT02676752 - Skin/Soft Tissue Elasticity in Head and Neck Cancer Survivors With Lymphedema and Fibrosis
Completed NCT02506530 - Treatment Pathway of Patients Suffering From a Breast Cancer Related Lymphoedema N/A
Completed NCT06323200 - Lymphedema Duration on Lymphatic Vessel Quality and Outcomes After LVA
Completed NCT02253186 - Clinical Study to Assess Safety and Efficacy of a New Armsleeve in the Management of Arm Lymphoedema N/A
Terminated NCT02020837 - A Pilot Study Assessing the Effect of Lymphaticovenous Micro-Anastomosis in the Treatment of Postmastectomy Lymphedema Early Phase 1
Recruiting NCT01318785 - Therapeutical Assessment of Compression Armsleeves for Lymphatic Indications Phase 2
Enrolling by invitation NCT02375165 - Biomarkers for the Detection of Lymphatic Insufficiency
Completed NCT02308488 - Study of Prone Accelerated Breast And Nodal IMRT N/A
Completed NCT00852930 - Low Level Laser Treatment and Breast Cancer Related Lymphedema Phase 4
Completed NCT01112189 - Use of Stem Cells in Lymphedema Post Mastectomy Phase 1/Phase 2
Completed NCT00743314 - Single-Photon Emission Computed Tomography, Computed Tomography Lymphoscintigraphy, and Intensity-Modulated Radiation Therapy in Treating Patients Who Have Undergone Surgery for Stage I or Stage II Breast Cancer Early Phase 1
Recruiting NCT06237907 - Pyroptosis and Ferroptosis in the Pathophysiology of Lymphedema
Terminated NCT01580800 - National Breast Cancer and Lymphedema Registry
Suspended NCT05366699 - LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy N/A
Completed NCT06249360 - Lymphatic System Reflux After Lymphatic Operation
Completed NCT06220903 - The Effect of Complex Decongestive Therapy in Patients With Lymphedema N/A
Terminated NCT02923037 - Hatha Yoga in Breast Cancer Survivors N/A
Recruiting NCT06041958 - Effects of Extracorporeal Shock Wave Therapy and Pulse Electromagnetic Field Therapy on Lymphoedema N/A